Guillain-Barré syndrome after rtPA therapy for acute stroke.
Bersano
A
A
Santoro
D
D
Prelle
A
A
Lanfranconi
S
S
Ranieri
M
M
Tadeo
C S
CS
Bresolin
N
N
Baron
P L
PL
D000208:Acute Disease; D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D020275:Guillain-Barre Syndrome / Q000139:chemically induced*; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects; D020521:Stroke / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator
J Neurosurg. 1992 Nov;77(5):694-9
1403109
Postgrad Med J. 1987 Jun;63(740):479-80
3432176
J Neuroimmunol. 2009 Jan 3;206(1-2):112-7
19058859
Ann Emerg Med. 1989 Mar;18(3):234-9
2493757
Lancet Neurol. 2008 Oct;7(10):939-50
18848313
Rev Neurol (Paris). 2002 Oct;158(10 Pt 1):887-91
12407295
BMJ. 1992 May 9;304(6836):1225
1515794
Neurochirurgie. 2005 Dec;51(6):604-6
16553335
Lancet. 2005 Nov 5;366(9497):1653-66
16271648
Neurology. 1998 Oct;51(4):1110-5
9781538
Drugs. 2004;64(6):597-610
15018590
Arq Neuropsiquiatr. 1997 Jun;55(2):315-8
9629394
Eur J Haematol. 1999 Nov;63(5):358-9
10580569